Unveiling the Therapeutic Prospects of IFNW1 and IFNA21: Insights into Glioma Pathogenesis and Clinical Significance

Overview

Journal Neurogenetics

Specialty Neurology

Date 2024 Jul 3

PMID 38958838

Authors

Hong Cheng

Yingjie Zhao

Xiaoli Hou

Fang Ling

Jing Wang

Yixia Wang

Yasen Cao

Affiliations

Soon will be listed here.

Abstract

Glioma, a type of brain tumor, poses significant challenges due to its heterogeneous nature and limited treatment options. Interferon-related genes (IRGs) have emerged as potential players in glioma pathogenesis, yet their expression patterns and clinical implications remain to be fully elucidated. We conducted a comprehensive analysis to investigate the expression patterns and functional enrichment of IRGs in glioma. This involved constructing protein-protein interaction networks, heatmap analysis, survival curve plotting, diagnostic and prognostic assessments, differential expression analysis across glioma subgroups, GSVA, immune infiltration analysis, and drug sensitivity analysis. Our analysis revealed distinct expression patterns and functional enrichment of IRGs in glioma. Notably, IFNW1 and IFNA21 were markedly downregulated in glioma tissues compared to normal tissues, and higher expression levels were associated with improved overall survival and disease-specific survival. Furthermore, these genes showed diagnostic capabilities in distinguishing glioma tissues from normal tissues and were significantly downregulated in higher-grade and more aggressive gliomas. Differential expression analysis across glioma subgroups highlighted the association of IFNW1 and IFNA21 expression with key pathways and biological processes, including metabolic reprogramming and immune regulation. Immune infiltration analysis revealed their influence on immune cell composition in the tumor microenvironment. Additionally, elevated expression levels were associated with increased resistance to chemotherapeutic agents. Our findings underscore the potential of IFNW1 and IFNA21 as diagnostic biomarkers and prognostic indicators in glioma. Their roles in modulating glioma progression, immune response, and drug sensitivity highlight their significance as potential therapeutic targets. These results contribute to a deeper understanding of glioma biology and may inform the development of personalized treatment strategies for glioma patients.

References

Wan R, Peng W, Xia Q, Zhou H, Mao X . Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma. CNS Neurosci Ther. 2021; 27(8):973-986. PMC: 8265949. DOI: 10.1111/cns.13654. View

Parmigiani E, Ivanek R, Rolando C, Hafen K, Turchinovich G, Lehmann F . Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. Dev Cell. 2022; 57(15):1847-1865.e9. DOI: 10.1016/j.devcel.2022.06.006. View

Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R . The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2022; 51(D1):D638-D646. PMC: 9825434. DOI: 10.1093/nar/gkac1000. View

Geeleher P, Cox N, Huang R . Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014; 15(3):R47. PMC: 4054092. DOI: 10.1186/gb-2014-15-3-r47. View

Takano S, Ishikawa E, Matsuda M, Yamamoto T, Matsumura A . Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol. 2014; 45(5):1837-46. PMC: 4203325. DOI: 10.3892/ijo.2014.2620. View

Zainulabadeen A, Yao P, Zare H . Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma. PLoS One. 2017; 12(1):e0170025. PMC: 5256985. DOI: 10.1371/journal.pone.0170025. View

Han X, Jin S, Yu L, Wang M, Hu X, Hu D . Interferon-beta inhibits human glioma stem cell growth by modulating immune response and cell cycle related signaling pathways. Cell Regen. 2022; 11(1):23. PMC: 9249963. DOI: 10.1186/s13619-022-00123-w. View

Hoekstra M, Bornes L, Dijkgraaf F, Philips D, Pardieck I, Toebes M . Long-distance modulation of bystander tumor cells by CD8 T cell-secreted IFNγ. Nat Cancer. 2020; 1(3):291-301. PMC: 7305033. DOI: 10.1038/s43018-020-0036-4. View

Frescaline G, Bouderlique T, Huynh M, Papy-Garcia D, Courty J, Albanese P . Glycosaminoglycans mimetics potentiate the clonogenicity, proliferation, migration and differentiation properties of rat mesenchymal stem cells. Stem Cell Res. 2012; 8(2):180-92. DOI: 10.1016/j.scr.2011.09.005. View

10.

de Aguiar C, Lobao-Soares B, Alvarez-Silva M, Trentin A . Glycosaminoglycans modulate C6 glioma cell adhesion to extracellular matrix components and alter cell proliferation and cell migration. BMC Cell Biol. 2005; 6:31. PMC: 1201133. DOI: 10.1186/1471-2121-6-31. View

11.

Wang L . Mitochondrial purine and pyrimidine metabolism and beyond. Nucleosides Nucleotides Nucleic Acids. 2016; 35(10-12):578-594. DOI: 10.1080/15257770.2015.1125001. View

12.

Basappa , Rangappa K, Sugahara K . Roles of glycosaminoglycans and glycanmimetics in tumor progression and metastasis. Glycoconj J. 2014; 31(6-7):461-7. DOI: 10.1007/s10719-014-9551-9. View

13.

Nakamizo A, Miyamatsu Y, Hirose H, Amano T, Matsuo S, Fujiwara M . Metabolic remodeling of pyrimidine synthesis pathway and serine synthesis pathway in human glioblastoma. Sci Rep. 2022; 12(1):16277. PMC: 9522918. DOI: 10.1038/s41598-022-20613-w. View

14.

Davis M . Epidemiology and Overview of Gliomas. Semin Oncol Nurs. 2018; 34(5):420-429. DOI: 10.1016/j.soncn.2018.10.001. View

15.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

16.

Ghotme K, Barreto G, Echeverria V, Gonzalez J, Bustos R, Sanchez M . Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis. Curr Top Med Chem. 2017; 17(12):1438-1447. DOI: 10.2174/1568026617666170103162639. View

17.

Yu R, Zhu B, Chen D . Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022; 79(3):191. PMC: 8924142. DOI: 10.1007/s00018-022-04219-z. View

18.

Lukhele S, Rabbo D, Guo M, Shen J, Elsaesser H, Quevedo R . The transcription factor IRF2 drives interferon-mediated CD8 T cell exhaustion to restrict anti-tumor immunity. Immunity. 2022; 55(12):2369-2385.e10. PMC: 9809269. DOI: 10.1016/j.immuni.2022.10.020. View

19.

Platanias L . Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005; 5(5):375-86. DOI: 10.1038/nri1604. View

20.

Lasfar A, Abushahba W, Balan M, Cohen-Solal K . Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol. 2011; 2011:349575. PMC: 3235441. DOI: 10.1155/2011/349575. View